[{"id":"exelixis","kind":"company","name":"Exelixis","route":"/companies/exelixis/","commit":"d1f1037d6e","date":"2026-09-10","author":"Jude Gomila","message":"Sources: official-website links on thirty more companies","file":"src/data/spikes/rcc.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"Official website\", url: \"https://www.exelixis.com\" }]"}]},{"id":"exelixis","kind":"company","name":"Exelixis","route":"/companies/exelixis/","commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/sponsor-aliases.ts","type":"added","fields":[{"field":"id"},{"field":"label"},{"field":"kind"}]},{"id":"exelixis","kind":"company","name":"Exelixis","route":"/companies/exelixis/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/spikes/hcc.ts","type":"changed","fields":[{"field":"tldr","before":"\"Maker of cabozantinib (Cabometyx), used in kidney, liver, thyroid and, since 2025, neuroendocrine cancers.\"","after":"\"Exelixis makes cabozantinib (Cabometyx), used in kidney, liver, thyroid and, since 2025, neuroendocrine cancers.\""}]},{"id":"exelixis","kind":"company","name":"Exelixis","route":"/companies/exelixis/","commit":"06611b41fb","date":"2026-09-08","author":"Jude Gomila","message":"Spikes: SCLC, mesothelioma, urothelial, RCC deep dives with structured outcomes, dosing, toxicity, regulatory events","file":"src/data/spikes/rcc.ts","type":"added","fields":[{"field":"id"},{"field":"kind"},{"field":"name"},{"field":"hq"},{"field":"country"},{"field":"companyType"},{"field":"website"},{"field":"ticker"},{"field":"asOf"},{"field":"sections"},{"field":"tldr"},{"field":"summary"},{"field":"drugs"},{"field":"cancers"}]},{"id":"exelixis","kind":"company","name":"Exelixis","route":"/companies/exelixis/","commit":"06899fbdf4","date":"2026-09-08","author":"Jude Gomila","message":"Spikes: hepatocellular carcinoma, biliary tract cancer, neuroendocrine tumours (deep, with structured outcomes, dosing, toxicity, regulatory","file":"src/data/spikes/hcc.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"hq"},{"field":"country"},{"field":"companyType"},{"field":"website"},{"field":"ticker"},{"field":"sections"},{"field":"tldr"},{"field":"summary"},{"field":"drugs"},{"field":"cancers"}]}]